Cytomegalovirus Meningoencephalitis After Rituximab Treatment for Primary Central Nervous System Lymphoma  

Oleh:

Siakantaris, Marina P ; Argyropoulos, Kimon V ; Ioannou, Savvas ; Papadopoulou, Vasiliki ; Tzeletas, George

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Neurologist vol. 19 no. 02 (Jan. 2015), page 35–37.
Topik: CMV; PCNSL; rituximab

Ketersediaan

Perpustakaan FK Nomor Panggil: N06.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The efficacy and safety of rituximab against B-cell lymphomas is well established. However, there has been an increased incidence of infectious complications after rituximab treatment, mostly hepatitis B reactivation and progressive multifocal leukoencephalopathy. This is the case of a 67-year-old patient with primary central nervous system lymphoma, who developed cytomegalovirus meningoencephalitis after receiving high-dose chemotherapy and rituximab. As there was no evidence of lymphoma relapse or additional immunosuppression, besides his previous treatment, an association between rituximab and cytomegalovirus meningoencephalitis cannot be ruled out.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali